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ABSTRACT
TITLE -  “A CLINICAL STUDY
ON CYSTOID MACULAR EDEMA DUE TO VEIN OCCLUSION AND 
ITS MANAGEMENT “
AIM - To compare the functional , anatomical and therapeutic outcome of 
patients with cystoid macular oedema due to retinal vein occlusion .
MATERIALS AND METHODS – This iaa  prospective study conducted at 
Uvea  and Retina  department, RIOGOH, Egmore,. About   30 patients were 
analysed and followed upto 3months on regular basis and as and when required.
OBSERVATIONS AND RESULTS :The mean age of presentationwas 53.2 ± 
5.6 years with a male : female ratio of 1.9:1. Supero temporalbrvo  was found to 
be the leading cause. The reduction in mean macular thickness was significant 
in patients .
After treatment all patients had a significant 2 Snellen line visualimprovement. 
The correlation between macular thickness and visualacuity was weak positive 
in post treatment. There was no   Increase in intraocular pressure noted. 
Hypertension was considered as a major association in developing vein 
occlusions.
CONCLUSION :The fall in Mean macular thickness after IVTA and Intra 
vitrealAntiVEGFwas statistically significant in all patients analysed.The visual
acuity improvement also was statistically significant (p<0.0001) butcorrelation 
with macular thickness was weak positive. Intravitrealtriamcinolone acetonide 
is a promising therapy in refractory cystoidmacular edema in terms of safety 
and effective.
KEYWORDS -Cystoid Macular Edema, Central Macular Thickness,  
VeinOcclusion, Visual Acuity.
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1INTRODUCTION
Retinal edema is most commonly seen  due to circulatorydisturbances and 
inflammatory conditions affecting the eye.  Macular edema is broadly
defined as an abnormal thickening of macula caused by excess 
accumulation of fluid in the extracellular spaces of retina.
Cystoid macular edema is condition caused by excess accumulation of 
fluid in cyst likespaces within the maculamostly in the outer plexiform 
layer. It is a commonpathological response to a wide variety of ocular 
insults. It is thought thatprostaglandin secretion and vascular endothelial 
damage causes fluidaccumulation in the relatively loose intercellular 
adhesions of outerplexiform layer which permits the formation of cystoid 
spaces.
Macular edemais the most important cause for loss of central vision in 
most patients.
Retinal vein obstructions is another common cause of CME. In patients 
with central retinal vein occlusion or a tributary branch occlusion and if 
macula is involved CME is a major cause of visual loss. ifedema is 
massive or chronic (8 months), it causes permanent diminution of vision 
2due to disruption of the intraretinal connections and to the intracellular 
damage suffered by the visual elements . Persistent CME may be 
associated with vitreomacular attachment or hyperlipidemia and 
cardiovascular disease. Finkelstein proposed a theory saying ischemic 
CME following branch retinal vein occlusion is often transient and, 
compared to perfused CME, has better prognosis for visual acuity. 
Another important sign of CME following venous obstruction is the 
development of fluid blood levels in central cystoid spaces which is more 
common in venous occlusion compared to other pathology.
Aphakic and Pseudophakic cystoid macular edema, commonlycalled as 
Irvine-Gass syndrome, has been recognised as a distinctentity since 1953 
after its description by Irvine and Gass and by Norton in1966. It is one of 
the most frequent and troublesome problem followingcataract surgery. 
With recent improvements in suture material production instrumentation , 
newer techniques and antibiotic therapy, loss of central vision secondary 
to changes in macula following uneventful cataract extraction has 
received recognition as a major complication of cataract surgery.
3REVIEW OF LITERATURE
HISTORY 
1877 -   Thevery first case of branch retinal vein occlusion was reported 
byLeber.
1899 –  Retinal vein occlusion is seen more commonly on the temporal 
than the nasal part of retina by Ammann
1928 – Koyanagi first reported association of vein occlusion with arterio 
– venous crossing and these causing macular edema.
1953 – Irvine reported a syndrome of spontaneous rupture of thehyaloid 
face following uneventful cataract extraction. There was decreased visual
acuity secondary to vitreous opacities and macular degeneration along 
with irritability of the eye affected.
1954 – Schepens noted attachment of the vitreous at the vitreousbase, 
disc and macula .
1955 - Schepens reported macular clouding followed by a macular break 
which in turn lead to retinal detachment, due to vitreous shrinkageand 
traction.
41965 – Tolentino and Schepens presented a series of cases of retinal 
edemaafter cataract extraction. In most of them they were able to 
demonstrate vitreous strands attaching to the macula and occasionally to 
optic disc. They attributed the change to vitreo-retinal traction.
1966 – Gass and Norton   framed  the title “Cystoid Macular Edema”. 
They illustrated the characteristicclinical and FFA picture and described 
in detail the biomicroscopicappearance of the condition
1966 – Iliff gave the vitreous traction theory.
1968 – Gass and Norton did partial open sky vitrectomy 
undermicroscopic control using cellulose sponge and scissors.
1970 – Mechanized vitrector was used for limbal and 
parsplanavitrectomy.
1977 – Miyake first used NSAIDs like topical indomethacin in 
thetreatment of CME following cataract surgery.
1983 – Katzen, Fleischman, Trokel used the Nd-Yag laser forvitreolysis.
51991 – Shahidi, Ogura determined that retinal thickness asmeasured by 
biomicroscopy and stereophotography correlates well withvisual acuity.
1995 – Arend and Remby used fluorescein angiography generatedwith 
scanning laser ophthalmoscope for early recognition of cystoidformation 
in CME.
1995 – Hee and Puliafito made use of optical coherence tomography
for objective monitoring of retinal thickness in patients with CME
ANATOMY OF MACULA
The macula or macula lutea (from Latin macula, "spot" + lutea, 
"yellow") is an oval-shaped pigmented area in thecenter of theretina . 
There is no anatomical landmark to define this zone on clinical
examination or on morphological basis. It is approximately a circle with
radius of 2.75mm centred at fovea (5.5mm in diameter). The 
yellowcolour of macula is due to xanthophyll pigments in ganglion cells. 
The
side walls of macula slope gently towards the fovea centralis. 
.Fovea centralis is the 
centre of macula and  measures 
thickness It is a small 
Foveola is 0.35mm in diameter and 0.13 mm in thicknessoccupying 
centre of fovea. It is situated 4mm temporal and 0.8mminferior to optic 
nerve head. Rod cone ratio is about 
in the centre of foveola is called umbo.
Parafoveal zone is an area measuring 0.5mm surrounding thefovea. Rod 
cone ratio is about 1:1.
Perifoveal zone is 1.5mm wide zone surrounding the parafovealarea.
6
smalldepression in the inner retinal surface in the
1.5mm in diameter and 0.25mm in 
pit that contains the largest number of cone cells
1:2 in this region.A small depression 
.
7BLOOD SUPPLY OF MACULA
Macular region is supplied by superior and inferior branches of central 
retinal artery. In 20% of individuals, cilioretinalartery also supply the 
macula.
Capillaries are arranged as three layered in the macula and they 
arereduced to single layer in the perifoveal area and in centre is the 
capillary
free zone of 400-600μm in diameter.
BLOOD RETINAL BARRIER
Outer Blood Retinal Barrier 
This is formed by the tight junctions (Zonulaeoccludens 
andZonulaeadherens) of retinal pigment epithelial cells. Helps to regulate 
the movement of solutes and nutrients from the choroid to the sub-retinal 
space
Inner Blood Retinal Barrier
The endothelial cells of retinal capillaries are bound together aboutthe 
lumen by intercellular junctions of zonulaeoccludens type and forms
the inner blood retinal barrier.
ANATOMY OF FOVEA
(1) Foveola (2) Fovea centralis (3) Parafovea (4) Perifovea
8
9MICROANATOMY OF MACULA
Retina at macula is made of three types of cells and their 
synapsesarranged from without inwards in the following layers
 Retinal pigment epithelium
 Layer of rod and cones
 External limiting membrane
 Outer nuclear layer
 Outer plexiform layer
 Inner nuclear layer
 Inner plexiform layer
 Ganglion cell layer (multilayered in comparison to rest of retina)
 Nerve fibre layer
 Internal limiting membrane 
In Cystoid Macular Edema there is accumulation of fluid betweenouter 
plexiform and inner nuclear layer of the retina.
FOVEA CENTRALIS
This region is predominated by cones and are arranged obliquelyforming 
the Henle’s layer
10
FOVEOLA
This region of retina contains cones and their nuclei covered bythin 
internal limiting membrane. Remaining retinal layers (Inner nuclearlayer, 
Inner plexiform layer, ganglion cell layer and nerve fibre layer) areabsent 
in foveola.
HENLE’S FIBRELAYER
The outer plexiformlayer of retina is made up of arborisation of axons of
rods and cones with bipolar cell dendrites. It includes Muller’s fibres and
Horizontal cell processes. This layer has a reticular structure but 
asmacula is approached it takes up a fibrous structure called Henle’s 
layer.
The fibres run vertically at first and then obliquely near macula andfinally 
parallel to surface which is thickest at macula and absent atfoveola. There 
is progressive disappearance of rods.(1)
ANATOMICAL PECULIARITIES OF MACULA CAUSING AN
EXAGGERATED RESPONSE TO PATHOLOGICAL 
PROCESSES
The peculiar susceptibility of the macula to a number of 
differentpathological processes, both local and general is called the 
“exaggerated
11
response of macula” (2). Anatomical causes for this are:
Vascular supply – The arcade arrangement of capillaries whicharise as 
terminal parts of an end artery system together with the centralavascular 
zone make the foveolar region a watershed. Local impairmentof 
metabolism whether from disturbances of perfusion and accumulation
of metabolites or from the effects of capillary damage leads 
toextracellular fluid collection at a quicker rate than they can be absorbed.
Also the capillaries at fovea are longer and vascular complexes arethinner 
than elsewhere hence they are more susceptible to noxioussubstances.
1. Tissue architecture – The processes of Muller’s cells runhorizontally in 
outer plexiform layer hence retina loses its compactnature and this laxity 
causes  large amount of extracellular fluidto be accumulated in the 
macular region leading to characteristiccystoid edema
2. Cellular constituents – The ganglion cells have high metabolicactivity 
and their dysfunction leads to rapid accumulation of tissuemetabolites. 
Most of these have a vasodilator effect and this alongwith the underlying 
hypoxia leads to edema.
3. Internal limiting membrane – The vitreous is an excellent diffusion
12
medium and the ILM provides little additional interference to theprogress 
of toxic substances diffusing across it. Inflammatorytoxins arising from 
the iris, peripheral choroid and pars plana maytraverse the vitreous and 
because of the thinness and adherence ofILM in foveal region, which  
may  disturb the function of cells which are highly concentrated around 
foveal rim and also affect the capillary permeability of the macular region
4. Choroid and RPE – The macular choroid and RPE are also the most 
important sites for degenerative changes which may behereditary, toxic 
or arteriosclerotic in nature. There is apredisposition for choroidal 
vascular disease with decompensationand hemorrhage in the central area.
EVALUATION OF MACULAR DISEASES
SLIT LAMP BIOMICROSCOPY-  Utilises high power convex lenses 
to obtain wide field of view of the fundus which is vertically inverted and 
laterally reversed and  provides high magnification with stereopsis to 
detect macular disease.
AMSLER GRID TEST - evaluates central 200 of visual field on 
fixation and henceuseful in screening and monitoring the macular disease. 
There are 7charts. Chart 1 is most commonly used. This chart consists of 
white gridon black background with 400 small, 5mm squares, each square 
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subtendsan angle of 10 when viewed at 33cm. Each eye is checked 
individually,with the chart held at 33cm with prior correction for 
presbyopia. Patientsare asked to maintain fixation on the central dot and 
comment on fourcorners, any missing areas on chart and wavy lines.
FUNDUS FLUORESCEIN ANGIOGRAPHY - Fluorescence is the 
property of certain molecules to absorb light of shorter wavelength and 
emit light of longer wavelength. S odium fluorescein is a water soluble 
orange dye, 3ml of 25% fluorescein is injected intravenously through
antecubital vein, 85% isbound to plasma proteins and remains 
intravascular. Passage of dyethrough retinal and choroidal circulations is 
studied through photographicsurveillance.
Phases in FFA – Choroidal phase, Arterial Phase, Arteriovenousphase, 
Venous phase, Recirculation phase
Causes of Hyperfluorescence – Autofluorescence, Pseudofluorescence, 
Window defect, Pooling, Leakage, Staining.
Causes of Hypofluorescence – Masking of Retinal fluorescence,Masking 
of Choroidal fluorescence, Filling defects.
OPTICAL COHERENCE TOMOGRAPHY
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OCT is a non invasive, non contact imaging system that provideshigh 
resolution cross sectional images of retina, optic nerve head and 
thevitreous.5
OCT is analogous to B-scan ultrasonography but uses near-infrared light 
interferometry rather than sound waves.
OCT is used to differentiate lamellar and full thickness macularhole, to 
determine treatment options in CNVM, monitoring the course ofCSR, 
retinal thickness map, to identify type of macular edema and tomonitor its 
course and so on.
 High Reflectivity – Nerve fibre layer, RPE, Choriocapillaries,
Pigment accumulation, Naevus, Neovascularisation, RPE
hypertrophy.
 Medium reflectivity – Plexiform layer.
 Low Reflectivity – Nuclear layer, Photoreceptors, Retinal edema,
Cystoid edema, Cavity, Cyst, Pigment epithelial detachment, Serous
retinal detachment
The macular edema patterns seen on OCT are as follow:
1. Sponge like Retina - It is mostly confined to outer retinal layers due to 
backscattering from intra retinal fluid.
2. Cystoid macular edema
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Cystoid spaces confined to outer retina mostly. In long standingcases they 
fuse to form large cyst.
3. Serous retinal detachment
Hypo reflective space under fovea. It may disappear followinglaser.
4. Tractional retinal detachment
Foveovitreal traction causes detachment of fovea. Its an indicationfor 
Pars Plana Vitrectomy to release traction. Laser will worsen 
macularedema in these cases.
5. Taut Posterior Hyaloid Membrane
Cystoid spaces confined to outer retina mostly. In long standingcases they 
fuse to form large cyst.
CYSTOID MACULAR EDEMA
The extracellular space of the retina usually constitutes a smallproportion 
of its total volume.4 Active transport of electrolytes and largermolecules 
from retina across the retinal pigment epithelium occurs in this space.
Disruption of either inner or outer retinal barrier leads to leakage of 
plasma proteins and water which leads to expansion of extracellular space 
of retina. This is often accompanied by accumulation of fluid in the outer 
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plexiform and inner nuclear layer of retina6. Retinal edema localized to 
macula is called macular edema leading to diffuse thickening of posterior 
pole. Accumulation of fluid in cystic spaces leads to cystoid macular 
edema.1,2
CAUSES OF CYSTOID MACULAR EDEMA
Cause of cystoid degeneration of macula as described by DukeElder(3)
are
1. Senile degeneration.
2. Vascular disorders - Arteriosclerosis, CRVO, CRAO, 
Retinalperiphlebitis, Hypertensive retinopathy, Diabetic retinopathy.
3. Inflammatory conditions - chorioretinitis, iridocyclitis.
4. Degenerative conditions of macula - Retinal dystrophies, Retinitis 
pigmentosa.
5 Trauma - usually in contusions or associated with retention of foreign 
body, radiation injury like eclipse blindness.
6. Glaucoma.
7. Hereditary macular dystrophy.
Other conditions as mentioned by Stephen J. Ryan are(4)
8. Drugs - Epinephrine maculopathy, Nicotinic acid
maculopathy.
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9. Post surgical - After any type of cataract surgery, vitrectomy,glaucoma 
procedures, penetrating keratoplasty.
10. Tumours - choroidalhemangioma, choroidal melanoma.
11. Retinal detachment.
12. Tractionalmaculopathies – Epiretinal membrane,Vitreomacular 
traction syndrome.
13. Optic nerve head pathologies – Optic disc pit, coloboma,diabetic 
papillopathy.
Retinal Vein Occlusion Induced Cystoid Macular Edema
In CRVO and BRVO, macular edema tends to be chronic, difficultto treat 
and causes a gross loss in visual acuity. Visual loss is exacerbated by 
macular haemorrhages, ischemia, secondary RPE changes like ERM.
Pathophysiology Elevation in intravascular pressure in the veins distal 
to occlusion site causes increase in transmural hydrostatic pressure in 
retinal capillaries causing a greater transudation of fluid into extracellular 
spaces.7
 Disruption of microscopic intraretinal connections due to cytokines
mediated by hypoxia in retina greatly facilitates extravasation of fluids as 
well as large protein molecule(5).
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 Development of fluid blood levels in central cystoid spaces is
characteristic of obstructive retinopathy.
Branch Retinal Vein Occlusion
Branch retinal vein occlusion, occurs at an arteriovenous (AV) crossing is 
the most common RVO. The artery and vein have a common adventitial 
sheath at the AV crossing with varying degrees of fusion of the vascular 
wall. Venous compression by the relatively sclerotic artery may result in 
turbulent flow, endothelial damage, thrombosis and occlusion. 1 Most 
BRVO occur in the superotemporal quadrant, due to the increased 
number of arteriovenous crossings in this quadrant. Because of their 
asymptomatic nature, nasal occlusions are less likely to be diagnosed .8
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CLINICAL FEATURES 
 Complaints of decreased vision or may be asymptomatic.
 Vision loss at presentation is related to the extent of macular 
damagefrom intraretinaledema,hemorrhage or capillary non-
perfusion. 
 In the acute  presentationthe involved retina typically shows 
venous dilation and tortuosity, superficial intraretinal hemorrhages, 
and/or cotton wool spots.
20
FFA
Findings include delayed venous filling in the area of occlusion, capillary 
non-perfusion, and macular edema in the early phase , as well as 
microvascular abnormalities in later stages.Long-term sequelae include 
sheathing of veins, vascular telangiectasias, the formation of collateral 
retinal vessels, 
Fig 1 – delayed filling in the venous phase and development of 
collaterals. Few capillary non perfusion areas are seen .
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Fig 2 – delayed filling in the venous phase along with blocked 
fluorescence suggestive of hemorrhages
Fig 3  -delayed filling in the early phase with leaks.
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OCTshows serous macular detachment and subretinal haemorrhage along 
with macular edema , cystoid in nature due to accumulation of the fluid .
Central Retinal Vein Occlusion presents with haemorrhage in all 4 
quadrants showing a tomato splashed appearance9. The occlusion 
typically occurs at or near the lamina cribrosa, where relative narrowing 
of the central retinal artery and vein contributes to turbulent flow and an 
increased risk of thrombosis, CRVO is classified as ischemic and non-
ischemic
CLINICAL PRESENTATION
Clinically, patients with CRVO present with sudden loss of central 
vision.. In the acute phase all four quadrants shows  features of venous 
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dilation and tortuosity, superficial and deep intraretinalhemorrhages, 
and/or cotton wool spots. There is usually disc edema and there may be 
macular edema and/or serous detachment. In CRVO, vision loss is 
primarily due to macular edema, macular hemorrhage, and perifoveal 
capillary non-perfusion in the ischemic variety10. Clinically, visual acuity 
<20/200, the presence of an afferent papillary defect, and extensive 
retinal hemorrhages are consistent with ischemic CRVO.
Although the severity of the ophthalmoscopic findings varies with the 
extent of retinal ischemia, ophthalmoscopy alone is not adequate to 
differentiate between ischemic and non-ischemic CRVO.
Hemi-Retinal Vein Occlusion:
Hemi-retinal vein occlusions are variants of central retinal vein 
occlusions that involve the superior or inferior half of the retina.12This is
due to an anatomic variation at the optic nerve head
24
OTHER CAUSES OF CYSTOID MACULAR EDEMA
Diabetic Cystoid Macular Edema
It is the most common cause of visual loss in patients with NPDR. This is 
best detected by slitlamp biomicroscopy. Incidence of macular 
edemaincreases with type of diabetes, duration of diabetes, age of onset, 
use of insulin, uncontrolled diabetes, associated risk factors like 
hypertension, hyperlipidemia, anemia,and nephropathy. It is more 
common in type 2 diabetes.11
Pathophysiology
Hyperglycemia is the main inciting factor which causes disruptionof 
retinal vasculature that breaks blood retinal barrier and leakage 
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frommicroaneurysms and capillaries. Focal retinal hypoxia causes an 
increase
in hydrostatic pressure that in turn increases luminal hydrostatic 
pressure.This causes dilatation of capillaries with disruption of tight 
junctionsbetween endothelial cells and favouring fluid egress and macular 
edema.
Clinical features Of Diabetic macular edema
1. Thickening of macula
2. Blurring of underlying choroidal vascular pattern
3. Loss of foveolar reflex
4. Cystoid spaces
5. Lipid exudation from leaking microaneurysms forming circinate
maculopathy.
Classification of type
1. Focal Edema – Areas of focal leakage from microaneurysms forming 
partial or complete ring of hard exudates delineated from adjacent healthy 
retina.
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2. Diffuse Edema – Areas of leakage from microaneurysms and dilated 
capillary segments throughout posterior retina causes diffuse edema. It 
differs from focal edema by
a)Diffuse edema is not associated with hard exudates.
b) It develops cystoid spaces more commonly and better seen in
late phases of FFA and on OCT as hyper reflective spaces
with hyper reflective septa.
c) It is bilaterally symmetrical.
d) It may disappear spontaneously even without laser only to reappear 
spontaneously.
e) Systemic features may be associated with exacerbations and 
amelioration of diabetic macular edema.
3. Ischemic Edema – It is associated with enlargement of FAZ, 
irregularties of FAZ, capillary budding into FAZ, widening of  
intercapillary spaces and capillary dropout in perifoveal area.14
Clinically Significant Macular Edema (CSME) defined as 
1. Thickening of retina within 500μm from centre of macula.
2. Hard exudates with retinal thickening seen within 500μm from centre 
of macula.15
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3. A zone of retinal thickening about 1 disc diameter in size, a portion of 
which is seen within 1 disc diameter from centre of macula.
FFA
Focal edema shows areas of leakage mainly from microaneurysmsin late 
phases. Diffuse edema shows dilated capillary network with areasof 
capillary nonperfusion with extravasations of dye in late phases. Ifleakage 
occurs in flower petal pattern, cystoid macular edema is present
POST OPERATIVE CYSTOID MACULAR EDEMA
It is the most common cause of loss of vision after cataract surgery.A 
higher incidence is seen when surgery is complicated by vitreous loss,
vitreous adhesions to the wound, iris damage or retained lensmaterial.
Patients with DM and Uveitis (vasoactive stimuli) are at a greater risk of 
developing CME
Pathophysiology
 Vitreous Traction Theory
Constant constriction and dilatation of pupil created pulling effecton the 
anterior vitreous strands which was transmitted to the vitreous baseand to 
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macula by presumed vitreous connections between posteriorhyaloid and 
surface of macula- VITREOUS TUG SYNDROME.
 Inflammation Theory
CME following cataract extraction can be seen in approximately 20% of 
uncomplicated cases.(6)
Eyes with CME nearly always demonstrate signs of 
intraocularinflammation and responds to steroid therapy. Aqueous 
humour contains
biochemically active principles known as Aqueous Biotoxic Complex 
factorswhich manifest biotoxic effects when it leaves its natural reservoir. 
Thesediffuse posteriorly through collapsed liquefied vitreous gel. The 
liquefiedvitreous anterior to retina assumes chemical and osmotic 
properties thatare not normally present resulting in outpouring of fluid 
from perimacularcapillaries.Since eye does not contain enzyme 15-Pg 
dehydrogenase todeactivate prostaglandins, their removal is dependent on 
active transportpump called Bito’s(23) pump located in the ciliary 
epithelium which isinoperable for atleast 3weeks post trauma.
 Anoxic Theory
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An association between CME and systemic conditions likehypertension, 
diabetes mellitus, arteriosclerotic disease is seen in whichanoxia could be 
a predisposing factor.
CME In ACIOL
Chronic uveal irritation may either stimulate production of intraocular 
inflammatory substances or may retard the absorption or removalof these 
substances by non pigmented epithelium of ciliary body. AnACIOL can 
press against anterior surface of iris or apply constantpressure over ciliary 
body which could trigger anterior uvealinflammation.
CME In PCIOL
1. No pupillary distortion and intact posterior capsule
a. Sulcus fixated IOL – chronic irritation of uveal tissuebecause of direct 
contact can lead to CME
b. In the bag IOL – Incidence of CME is low.
2. Pupillary distortion – Distortion by pupillary capture or bysynechiae 
between remnants of anterior capsule and posteriorsurface of iris can lead 
to persistent uveal irritation leading toCME. The degree of irritation is not 
as great as produced by pupildistorted by wick of vitreous adherent to 
corneoscleral wound.
CME In Phacoemulsification
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There could be a greater incidence during learning curve becauseof 
increased intraocular manoeuvring and greater risk of complications
CME In Posterior YagCapsulotomy
1. Primary Surgical Posterior Capsulotomy
There is a higher incidence of CME because posterior capsule acts as a 
barrier to posterior diffusion of inflammatory mediators and to anterior 
movement of vitreous.
2. Secondary Nd-YagCapsulotomy
 Broken capsule no longer acts as a barrier for posterior
diffusion of inflammatory mediators.
 Inadvertent rupture of anterior hyaloid face.
 Post laser intraocular inflammation.
CME IN UVEITIS
Pathophysiology
Disruption of blood retinal barrier secondary to inflammatorymediators 
like Cytokines, Interferon-gamma, Interleukin-2 and 10, TNF-alpha .
THEORIES CONCERNING ORIGIN OF CYSTS OF CME
Intracellular Theory
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Yanoff et al. proposed that cysts develop from degeneratingMuller’s 
cells. Initially these cells demonstrate edema which graduallyincreases 
until cytoplasm of cells begin to develop vacuoles. Theseedematous cells 
gradually expand until cell walls break and adjoiningcells form larger 
cavities leading to cysts in CME. A breakdown in blood retinal barrier or 
anoxia is the prime cause for edema.
Extracellular Theory
Gass, Anderson and Davis proposed that cysts arise fromexpansion of 
extracellular spaces of retina by serous exudation seen within the OPL 
and inner nuclear layer. This involves leakage of serous exudates from 
perifovealintraretinal capillaries and sometimes from disc capillaries. 
These exudates form small cavities with  fluid  in OPL of Henlewhich 
acts like a sponge because of peculiar nature of macula. 
CLINICAL FEATURES OF CYSTOID MACULAR EDEMA
SYMPTOMS
It is usually asymptomatic. If severe, defective vision,metamorphosia, 
scotomas can occur.
SIGNS
Fundus
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Characteristic honey comb like lesion showing one or more cystoid
spaces centrally with many small oval spaces around them.
Sometimes only loss of foveal reflex is seen.
Cystoid spaces are best seen with red free filter which makes innerwalls 
visible.
Retina may be markedly thickened and lesion as large as 1.5 – 2 disc 
diameter. Some cases are associated with disc edema.
Anterior segment- Usually shows signs of inflammation. Theanterior 
hyaloid face is broken or intact and vitreous shows cells, 
vitreousopacities and posterior vitreous detachment.
COLOUR FUNDUS PHOTOGRAPH OF CYSTOID
MACULAR EDEMA
CLINICAL EVALUATION OF CYSTOID
MACULAR EDEMA
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1. VISUAL ACUITY
Best corrected visual acuity and with pin hole should be assessed.Loss of 
vision depends on the involvement of macula. Severity of visionloss 
correlates well with amount of macular edema.14
2. PERIMETRY
Field charting by perimetry may reveal scotoma corresponding toareas of 
involvement in fundus.
3. COLOUR VISION
The most common defect is blue . In diabetes the sensitivity of bluecones 
is depressed. These are best detected by Farnsworth munsell 100 hue test.
4. DIRECT OPHTHALMOSCOPY
Monochromatic light is better for detecting subtle macular changes,hence 
red free light is used. But lack of stereoscopic view is a disadvantage.
5. SLIT LAMP BIOMICROSCOPY WITH 90D, 78D, HRUBY
LENS, GOLDMANN THREE MIRROR CONTACT LENS
The optical section of convex anterior walls of cysts can be seenoverlying 
empty vesicles tightly packed together with their interfacespresenting a 
spidery pattern.
With slit beam, it is possible to see a network of interlacing fine refractile 
lines by retroillumination. Advantages of using stereopsis and slit lamp 
optics
6. INDIRECT OPHTHALMOSCOPY
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This provides an entire view of retina allows examiner to have 
anunderstanding of the cause in various pathological features of retina.It 
gives less magnification.
7. RETINAL PHOTOGRAPHY
Photographs are taken with fundus camera and selected films andcolour 
filters. Red free light is used for detecting subtle changes in ILMand 
NFL.
8. STEREOPHOTOGRAPHY
Two photographs are taken alongparallel axes on either side ofdilated 
pupil producing stereoscopic pair. The separation of images canbe 
adjusted to reproduce the normal depth relationships and to allowdepth 
measurements.
9. MADDOX ROD TEST
The patient is asked to look at distant light through a Maddox rod.If the 
red line is continuous and unbroken, macular function is good.
10. AMSLER GRID TEST
Central distortion of the grids or a relative central scotoma
11. ENTOPTIC IMAGERY
The globe is steadily and firmly massaged through the closed lowerlids, 
with bare lighted bulb of a torch. The entire vascular tree of theretina is 
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seen on an orange background. Any blanks or scotoma in thecentral area 
implies macular involvement.17
12. POTENTIAL ACUITY METER
It is for differentiating between visual loss from anterior 
segmentPathology and macular disease. The PAM attaches easily to a 
standard slitlamp and projects a Snellen’s visual acuity chart into eye 
using an aperture which is  1.5mmdiameter. The patient is tested at 
different points on thecornea in an attempt to project through the clearer 
areas in the lens.
13. MACULAR PHOTOSTRESS TEST OR AFTER IMAGE
SCOTOMETRY
The patient is asked to look at a flash light held 2cm from the eye for 10
seconds. The time it takes for visual recovery to one line less than 
thevisual acuity determined prior to this test is measured. The 
normalrecovery time is 55seconds.23Longer recovery time, upto 90-180 
seconds
implies macular dysfunction even though the area may 
appearanatomically normal. The rapidity of recovery relates to the rate of 
visual
purple regeneration and rapidity of vitamin A transport from RPE 
tophotoreceptors. Difference between two eyes is also significant.
14. CLINICAL INTERFEROMETERS
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In cases of opaque media, beams of coherent light from two pointsources 
are directed through the clearest area of the lens to retina.Interference 
fringes on the retina are formed wherever the two beamsoverlap and by 
varying the width of the inter fringe pattern, the visualacuity can be 
determined.
15. ELECTROPHYSIOLOGICAL ASSESSMENT
Foveal ERG is a test of the temporal responsiveness of the central100 of 
the retina and requires integrity of the outer retinal layers,especially 
Muller’s cells. 19FERG is usually abnormal in 35% of eyes withCME. 
Pattern ERG reflects the inner retinal layer function. It is usuallyabnormal 
in 53% of eye with CME. It is the test of the temporalresponsiveness of 
central 100 of the retina.
16. VISUAL EVOKED POTENTIAL
In macular disease with fluid accumulation, the VEP showsamplitude 
reduction depending on the decreased visual acuity with nochange in 
latency.
IMAGING MODALITIES IN CYSTOID MACULAR EDEMA
 FUNDUS FLUORESCEIN ANGIOGRAPHY
FFA is mandatory for following purposes:
 Confirm and document macular changes
 Deciding the management
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 Follow up.
In CME, within 1-2 minutes of injection, in the arteriovenous
phase, early leakage of the dye in the parafoveal area is seen. In 
someinstances, focal points of leakage with confluence of leaking areas 
will be
noted. 20A characteristic flower petal appearance is evident in 
latearteriovenous phase in the parafoveal region. Fovea itself appears 
dark
and does not always show leakage. The late phase shows marked 
edemawith persistent pooling of dye in cystoid spaces.
The dark septae in the macular area which compartmentalize thepattern 
are because of the Muller’s fibres. The spaces appear 
tointercommunicate. Usually there is considerable leakage of dye 
intovitreous and aqueous anteriorly. In some patients with disc edema, 
there
may be leakage of dye into optic nerve and peripapillary retina.
 OPTICAL COHERENCE TOMOGRAPHYThis investigative 
modality can also be used for diagnosis andfollow up. It has added 
advantage of being non-invasive.
In addition parameters like macular thickness can be quantified 
onsubsequent visits.
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Cystoid spaces confined to outer retina mostly.In long standingcases they 
fuse to form large cyst. 
FFA PICTURE SHOWING CHARACTERISTIC
FLOWER PETAL LEAKAGE PATTERN
OCT PICTURE SHOWING CYSTOID SPACES
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TREATMENT MODALITIES FOR MACULAR EDEMA
1. LASER PHOTOCOAGULATION
Macular edema secondary to vascular causes like diabeticretinopathy and 
retinal vein occlusions respond well to focal and gridlaser 
photocoagulation. Focal laser is used to close microaneurysms andgrid 
laser stimulates RPE pump to clear the edema.The Early Treatment for 
Diabetic Retinopathy Study (ETDRS)established guidelines for laser 
treatment in diabetic macular edema(7).Laser treatment is indicated for 
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clinically significant macular edema asper definition stated before. 
Moderate visual loss was reduced to 50% inpatients who received laser 
therapy in ETDRS.
Grid laser has better response in patients with BRVO but not inCRVO. 
In Branch Vein Occlusion Study, 65% of grid laser treated eyesgained 
atleast 2 lines of better vision, compared with 37% of untreated eyes(8).
InCVOS , grid laser did not have any significanteffect on vision, although 
there was a trend towards better vision inpatients aged <60 years who 
underwent laser treatment
2. MEDICAL MANAGEMENT
TOPICAL THERAPY
Several studies have documented the utility of topical NSAIDs forboth 
the prevention and treatment of macular edema after lens removal 
surgery. A double masked, randomized, placebo controlled trial 
toevaluate the effect of Ketorolac 0.5% ophthalmic solution on 
chronicpseudophakic and aphakic CME determined that this drug is 
beneficial
for the primary outcome measure (Snellen’s acuity)(10). The efficacy of
topicalFlurbiprofen 0.03% and Indomethacin 1% in 
preventingpseudophakic CME revealed a reduced incidence of clinical 
and angiographic CME in the early postoperative period. Recently, two 
new topical NSAIDs,
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Bromfenac 0.09% and Nepafenac 0.1% have been FDA approved for
cataract surgery inflammation and pain. 25There have been 
reports,particularly for Nepafenac, of their potential for preventing 
pseudophakicCME.(11) Nepafenac is a prodrug that is converted after 
cornealpenetration to Amfenac, a potent NSAID. In one animal 
model,Nepafenac was shown to inhibit prostaglandin in the vitreous 
humour to a
much greater extent than other traditional NSAIDs. Whether this efficacy 
will translate into improved prevention or treatment of pseudophakic
CME is currently under investigation.22
Corticosteroids drops alone or in combination with NSAID drops,have 
been studied for the treatment of pseudophakic CME. Treatmentwith 
topical NSAIDs appears to be more effective than topical steroidsalone. 
However, combination therapy with topical NSAIDs andPrednisolone 
acetate was superior in treating macular edema.
Consensus for topical NSAIDs use has not been established formally,
however, the standard of care for many surgeons is to use bothNSAIDs 
and topical steroids for atleast 1 to 2 days preoperatively and forseveral 
weeks postoperatively. In higher risk patients, such as those withpre-
existing ocular inflammation or diabetes, extended preoperative 
andpostoperative use is typically employed. Patients must be monitored 
for
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side effects of both NSAIDs (corneal toxicity) and corticosteroid 
use(increased intraocular pressure).
INTRAVITREAL STEROIDSCorticosteroids by their anti 
inflammatory effect will contribute to reduction in edema. Increased 
diffusion by modulation of calcium channels also could account for 
efficacy of corticosteroids.(15)In last few years, intravitreal triamcinolone 
(IVTA) has gained
Widespread use as a treatment in all forms of macular edema. 
IVTAreduces retinal thickening on OCT and improves vision in a 
substantial
number of patients. Patients with cystoid component respond better. The
duration of effect varies and macular edema recurrence and visual decline
are observed 4 to 6 months after injection. Repeated therapy is 
oftenlimited by side effects. Intraocular pressure elevation occurs in about 
one
third of patients, which can (rarely) require glaucoma 
surgery.26Acceleration of cataract formation, endophthalmitis are 
othercomplications associated with theprocedure which should be 
considered and discussed with the patient as a part of informed consent.
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IVTA has also been used in macular edema associated with 
veinocclusion. A recently published 1 year study revealed a short term 
visual
benefit in patients with CRVO associated macular edema who 
weretreated for macular edema with IVTA, although their vision 
generallyreturned to pretreatment levels at 1 year despite repeated 
injections(16). It
has also been observed that rate of intraocular pressure rise and need for
glaucoma surgery appears to be higher in this subset of patients than 
inthose with diabetic macular edema. The SCORE (Standard Care 
VsCorticosteroid for Retinal Vein Occlusion) Study, a National Eye 
Institute
– sponsored randomized clinical trial of intravitreal steroid for BRVO and
CRVO associated Macular edema clearly mentions the benefit of IVTAas 
compared to standard therapy in CRVO. In cases of macular edemadue to 
BRVO, IVTA and Grid laser shows a comparable response,however, 
IVTA can be used for macular edema not responding to gridlaser therapy. 
Finally IVTA has been used in uveitic CME. 
INTRAVITREAL DRUG DELIVERY SYSTEMS
Recently multiple alternative steroid delivery devices has arrivedfor 
treatment of macular edema. Currently four 
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corticosteroidbasedintravitreal implants under development.Which
include:
Dexamethasone biodegradable implant (Posurdex®)
Helical triamcinolone acetonide implant (I-vation™ )
Fluocinoloneacetonide implant (Retisert®)
Fluocinoloneacetonide – based implant that is injectable
(Medidur™)
OZURDEX is an intravitreal implant containing 0.7 mg (700 
mcg)dexamethasone inthe NOVADUR solid polymer drug 
deliverysystem.It is effective in reducing macular edema for a period of 3 
months.
INTRAVITREAL ANTI VEGF COMPOUNDS
Anti VEGF agents work to restore the normal permeability of theblood 
retinal barrier. Pegaptanib sodium, an anti VEGF pegylatedaptamer, was 
used in treating DME .Patients received atleast 3injections at 6 week 
intervals and were followed for 36 weeks. Thepatients assigned to 
pegaptanib were more likely to gain atleast 10 letters(34% vs 10%, 
p=0.003) showed a reduction in centralmacular thickness (42% vs 16%, 
p=0.02) and at follow up examinationswere deemed less likely to need 
additional photocoagulation therapy(25% vs 48%, p=0.04).
45
Ranibizumab (LucentisTM), another intravitreal anti VEGF agentthat has 
been FDA approved for treatment of wet ARMD was studied in a small 
series of 10 patients with DME and found to significantly reduce foveal 
thickness and improve vision(19). Larger randomized trials are necessary 
to assess the significance of this preliminary finding.27In cases of diffuse 
DME that failed other treatments, intravitreal
injection of Ranibizumab was associated with improved vision and
decreased retinal thickness 12 weeks after the first injection(20). Most of
the patients received >1 Ranibizumab injection during follow up
Bevacizumab (AvastinTM) is a recombinant, humanized, monoclonal 
antibody was found to act against VEGF. Avastin has received 
FDAapproval as an intravenous drug for treatment of metastatic colon 
cancer.
An intravitreal formulation was first used off label for the treatment of
ARMD.
Recent study of intravitrealbevacizumab treatment for macular edema in
patients with CRVO revealed a significant decrease in mean central
thickness andimproved visual acuity (defined as halving the visual angle) 
in 14 of 16 eyes(21). Patients had received an average of 2.8 injections and 
werefollowed for a mean of 3 months. Noadverse outcomes occurred. 
These encouraging short term results need tobe validated in prospective 
studies. Bevacizumab has been tried inpatients with macular edema 
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secondary to uveitis. In one case series, inwhich patients were followed 
for atleast 2 months after a singleintravitrealinjection, about 70% of 
treated patients had a decrease infoveal thickness but only 40% of 
patients had improved visual acuity by>2 lines.(22) Thus for patients with 
difficult to control macular edema,bevacizumab may be a therapeutic 
option with reasonably goodoutcomes.
SEQUELAE OF CME
Permanent macular degeneration may arise secondary to 
prolongedchronic CME. The cystoid spaces of the macula may coalesce 
together so
that all retinal elements disappear except for the ILM. After the ILM also
disintegrates, a lamellar hole is formed which may be one fourth to one
third disc diameter in size. In the presence of lamellar hole, the 
visualacuity may continue to be good because of retention of some 
percipient
elements.
AIM OF THE STUDY
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To study the functional, anatomical and therapeutic outcome of patients 
with cystoid macular oedema secondary to retinal vein occlusion .
PRIMARY OBJECTIVES
To analyse the prevalence,etiopathogenesis, causes , to analyse the 
functional and anatomical outcomes ( central macular thickness )  and 
current treatment trends.
SECONDARY OBJECTIVES
To analyse  most common cause, effectiveness of treatment , frequency 
of the treatment and follow up of the patients.
INCLUSION CRITERIA
Patients presenting with 
1. Patients male or female  18 years old or more.
2. Patients who have not undergone any form of treatment for disease 
elsewhere.
3. Macular edema secondary to vein occlusion confirmed by fundus 
evaluation  , optical coherence tomography and fluorescein angiography 
4. BCVA worser  than 6/ 12
EXCLUSION CRITERIA 
Patients presenting with 
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1.Any previous treatment of macular oedema such as 
intravitrealbevacizumab, laser photocoagulation ,intravitreal 
triamcinolone or vitrectomy  done elsewhere before presenting to our 
centre.
2. Any significant media opacity which  precludes fundus evaluation and 
renders the diagnosis uncertain.
3. patients with vein occlusion with associated  vitreous 
haemorrhage,macular ischemia at presentation that contributes to 
decreased visual acuity.
4.Presence of fovealatophy, severe pigmentary changes dense subfoveal 
haemorrhage  , confluent subfoveal hard exudates or any other condition 
that may influence functional recovery of macular edema.
REFRACTORY MACULAR EDEMA 
All eyes of retinal vein occlusion induced macular edema received laser
photocoagulation and which were refractory to treatment withcentral 
macular thickness more than 300μm.
All the patients who were pseudophakic received Intravitreal 
Triamcinolone acetate along with topical NSAIDS when central macular 
thickness was found to be more than 300 microns. 
                         MATERIALS AND METHODS
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This was a prospective study carried out on the patients presenting to 
uvea and retina services at regional institute was registered, evaluated and 
followed up during the study period.
About 30 patients were evaluated for a period of 6 months.
A detailed history of the patient will be taken. Complete general 
examination and vitals measurement will be performed. Ocular 
examination including visual acuity ( usingsnellen’s chart with refractive 
correction ),  anterior and posterior segment will be evaluated. Slit lamp 
examination, and fundus examination using Direct, slit lamp 
biomicroscopy 90D and indirect ophthalmoscopy will be done. Field 
charting, IOP ( goldmannapplanation tonometry ) ,  will be measured. 
Fundus fluorescein Angiogram and Optical coherence tomography ( for 
assessing the central macular thickness ) was done. Laboratory 
investigations will be analysed. Examination of  RS, CVS ,CNS will be 
performed.
Radiological imaging ( carotid Doppler )  will be done and analysed for 
appropriate patients. Patients will also be referred to neurology,  
physician, diabetologist for expert opinion whenever indicated.
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Patients will be managed according to their appropriate diagnosis by 
either conservative treatment or surgical intervention. Response of the 
patients to the treatment and the incidence of complications in them will 
be assessed in the follow-up period.
All patients who had cystoid spaces in macular region on OCT,
who were refractory to treatment like grid and focal 
laserphotocoagulation in vascular causes and topical anti-inflammatory 
drugs
and grid laser photocoagulation in pseudophakic cases were subjected to
treatment with intravitreal triamcinolone acetonide injection and 
intravitrealanti VEGF injection. (ranibizumab )
A commercially available Triamcinolone acetonide withoutpreservative 
(CORTEYE 40mg/ml) is available. Under aseptic techniquesusing 5% 
povidone iodine and topical antibiotics, 4mg in 0.1ml 
oftriaminoloneacetonide was injected intravitreally in 
superotemporalquadrant via parsplana after taking informed consent. 
After injection, intraocular pressure and central retinal artery perfusion 
was checked. Patients were instructed to administer topical antibiotics for 
1 week. 
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Similarly  commercially available intravitreal anti VEGF Ranibizumab 
injection ( lucentis ) was given for patients with cystoid macular edema 
more than 300 microns. It was mostly was given for phakic eyes. About 
0.5mg /0.05 ml was given about 4mm away from the limbus in the supero 
temporal quadrant under sterile aseptic precautions after taking an 
informed consent. The intraocular pressure was checked and central 
retinal artery perfusion was looked for. Patients were followed 
accordingly.
FOLLOW UP 
Patients were followed up 1stweek , 3rd week ,  6 weeks , 3rd month and as and 
when required. During there follow up periods at each visit anterior segment 
examinationby slit lamp biomicroscopy, intraocular pressure with 
Goldmannapplanation tonometry, visual acuity recording with Snellen’s 
chart andfundus examination by +90 D was done.  A repeat OCT was 
done in the 6th week and 3rd  month.
GUIDELINES FOR INTRAVITREAL INJECTION
1. Povidone iodine application for ocular surface, eyelid and eyelashes.
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2. Use of eye speculum and avoid contamination of the needle with eyelid 
margin.
3. Avoid extensive massage of eyelids both pre and post injection.
4. Adequate use of topical anaesthetics.
5. Avoid prophylactic and post injection paracentesis.
6. Intraocular pressure to be checked following injection.
7 . Dilated fundoscopic examination should be done followinginjection to 
look for central retinal artery perfusion and intraocularlocation of the 
drug.
MAIN OUTCOME MEASURES
1. Best corrected visual acuity
2. Central macular thickness (μm) with OCT
3. Intraocular pressure (mm Hg) measurement with 
Goldmann’sapplanation tonometry.
INTRAVITREAL  INJECTION
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Figure - depict administration of Triamcinolone acetonideintravitreally 
through parsplana route.
ANALYSIS AND RESULTS
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1. AGE DISTRIBUTION
Totalnumber of patients in our study were 30 patients. 
The range was between 45 – 65 years including both males and 
females.
Majority of patients belonged to the age group of 50 to 55 years of 
age. 
An equal distribution was found between the age groups of 45 to 
50 and 56 to 60 years.
Mean age of presentation was 53.2 ± 5.6 years. The youngest 
patient was 46 years old and the oldest patient was 61 years old.
AGE (YEARS) FREQUENCY PERCENTAGE (%)
0%
5%
10%
15%
20%
25%
30%
35%
40%
45 - 50
45 – 50
50 – 55
55- 60
60- 65
2. SEX DISTRIBUTION
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51- 55 56 - 60 61 -65
age distribution
9 30
11 36
9 30
1 3
percentage
SEX
MALE
FEMALE
In this study, there was a slight male preponderance, males
60% of patients. Majority of them were in 50 
3.LATERALITY
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NUMBER PERCENTAGE
18 60%
12 40%
accounting for 
-55 yearsage group.
sex distribution 
male 
female
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EYE NUMBER PERCENTAGE
RIGHT 19 63 %
LEFT 11 37%
In this study, incidence of cystoid macular edema was more in righteye 
(63%).
4. ASSOCIATION OF DIABETES WITH CME
RE
LE 
0 5 10 15 20
RE
LE
RE LE
number
DIABETES
YES
NO
0 20
yes
no
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NUMBER PERCENTAGE
20 66.67%
10 33.33%
40 60 80
percentage
percentage
59
In this study it was found that out of the 30 patients evaluated about 20 
patients were diabetic. It accounted for about 66.67 %  of total number of 
patients, hence found to be one of the major risk factor.
Diabetes Mellitus
yes
no 
STAGE OF RETINOPATHY
MILD NPDR
MODERATE NPDR
SEVERE NPDR
VERY SEVERE NPDR
PDR
TOTAL
Among the total of 20 diabetic patients 
of the patients, MODERATE NPDR in 6 (30%)   patients, SEVERE 
NPDR in 9 ( 45 % ) patients, VERY SEVERE NPDR in 2 (10%) patients 
and PDR in 2 (10%) patients 
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MILD NPDR
MODERATE NPDR
SEVERE NPDR
VERY SEVERE NPDR
PDR
NUMBER PERCENTAGE
1 5%
6 30%
9 45%
2 10%
2 10%
20 100%
MILD NPDR was see in 1 ( 5%) 
5. ASSOCIATION OF HYP
HYPERTENSION
YES
NO
Among the 30 patients evaluated 26 patients accounting for about 
80% were found to be hypertensive. This concludes that 
hypertension is one of the major risk factor in developing 
vein occlusion.
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hypertension
yes
no
ERTENSION. 
NUMBER PERCENTAGE
24 80%
6 20%
retinal 
6. TYPE OF VEIN OCCLUSION CAUSING CME
VEIN OCCLUSION
CRVO
BRVO
HRVO
MTVO
In this study  cystoid macular edema
patients affected   with branch retinal vein occlusion. It accounted 
for total of 70 %.  CME due to CRVO was seen in 20% . CME due 
to hemi retinal vein occlusion was seen in 6.67 %.  And CME due 
to macular tributary vein occlusion was 
concluding that the branch retinal vein occlusion is a major cause 
for developing cystoid macular edema.
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NUMBER PERCENTAGE( %)
6 20
21 70
2 6.67
1 3.37
was seen maximum in 
seen in 3.33 % .Hence 
CRVO
BRVO
HRVO
MTVO
7. RELATIONSHIP OF IOP MEASUREMENTS
The IOP of most of the patients ranged between 12 to 18 mm hg. 
Most of the patients had a norm
0
2
4
6
8
10
12
12- 14
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al IOPof 14 ± 2 mmhg.
14- 16 16 - 18 
IOP in mm hg 
number
8 . VISUAL ACUITY 
VISION
1/60 – 2/60 NIP
3/60 – 4/60 NIP
5/60 – 6/60 NIP
6/36 – 6/24 
TOTAL
In the above study it was found that most of the patients vision ranging 
between 5/50 – 6/60 NIG NIP .it accounted for 46.6 %. About 10 % of 
the patients had the vision between 1/60 
had the vision between 3/60 
between 6/36 – 6/24 
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NUMBER PERCENTAGE( %)
3 10
7 23.3
14 46.6
6 20
30 100
– 2/60 NIP. 23.3 % of patients 
– 4/60 NIP. About  20% patients h
VISION 
1/ 60 - 2/60 nip
3/60 - 4/60
5/60 - 6/60
6/36 - 6/24
ad a vision 
CENTRAL MACULAR THICKNESS
9 . CENTRAL MACULAR THICKNESS
CMT ( MICRONS)
300-399
400 – 499
500 – 599
600 – 699
700 – 799
800 -899
900 – 999
Among the 30 patients evaluated, the highest number of patients had the 
central macular thickness ranging between 500 
was found to be 559.6 ± 216.27μm
ranging between 5/60 to 6/60. Hence all these pat
intervension. 
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300 -
400-
500-
600-
700-
800-
900 -
( CMT ) PRETREATMENT
EYES AFFECTED PERCENTAGE (%)
4 13.33
8 26.67
9 30
5 16.67
1 3.33
2 6.67
1 3.33
– 599μm.  The average 
These patients had a visual acuity 
ients needed surgical 
399
499
599
699
799
899
999
10 . TREATMENT 
All the patients in this study were subjected to surgical intervension based 
on the OCT finding of central macular thickness of more than 300 
microns. These patients had features of cystoid macular edema
well. About 6 patients among the 30 were found to be pseudophakic. 
These patients were  given intra vitreal triamcinolone acetate. And other 
patients were give intra vitreal anti VEGF ranibi
TREATMENT
IV ANTI VEGF ( ranibizumab )
IV TA
0
10
20
30
40
50
60
70
80
IV ANTI VEGF
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zumab injection.
NUMBER 
OF EYES
PERCENTAGE 
(%)
24 80
6 20
IVTA
TREATMENT
PERCENTAGE
on FFA as 
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DATA ANALYSIS IN RETINAL VEIN OCCLUSION
MACULAR EDEMA
                 PRE TREATMENT MACULAR THICKNESS
CMT ( MICRONS) EYES AFFECTED PERCENTAGE (%)
300-399 4 13.33
400 – 499 8 26.67
500 – 599 9 30
600 – 699 5 16.67
700 – 799 1 3.33
800 -899 2 6.67
900 – 999 1 3.33
The average was found to be 559.6 ± 216.27μm
                POST TREATMENT MACULAR THICKNESS
CMT 6 WEEKS 3 MONTHS
Numberof  
EYES
% Number 
of eyes
%
< 200 0 0 2 6.67
200 – 299 6 20 5 16.67
300 – 399 6 20 16 53.33
400 – 499 10 33.33 6 20
500 – 599 5 16.67 1 3.33
600 – 699 2 6.67 0 0
700- 799 1 3.33 0 0
The mean macular thickness at 6 weeks and  3 months post
intervention were 429.5 ± 90.31 μm (S.E – 19.02 ) and 333.86 ± 58.41
μm (S.E – 11.92) respectively
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Paired t test showed that there is a significantdifference in centralmacular 
thickness before and after Intra vitreal injection at 6 weeks &  3months  ‘ 
p’ values being 0.0179, 0.009 respectively.
The mean reduction in macular thickness at 6 weeks and 3 months post 
intervention were 276.91 ± 89.53 μm (S.E – 26.99) and 450.55 ±126.40 
μm (S.E – 38.11) respectively.
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DISCUSSION
AGE DISTRIBUTION - In this study of patients, majority of the 
patients (75%) belong to 5th and 6th decades. This may be due to the fact 
that most of cataract surgeries take place in this age group and prevalence 
of systemic diseases like DM and HT is more common in this age group. 
We had 9 casesbelow 50 years accounting for 30%of patients. Previous 
studiesshowed similar involvement. (Daniel M.Taylor et al.(21) Survey 
ophthalmology)
SEX DISTRIBUTION The study revealed a slight Male preponderance 
with a male to female ratio of 1.9:1.
LATERALITY
In this study, RE (63%) was more commonly involved than  LE(37%),
ETIOLOGY
BRVO shares the highest proportion of 70% followed byCRVO (20%), 
followed by HRVO ( 6.6%) last being macular tributary vein occlusion 
(3.3.%).
CME IN RELATION TO SURGICAL COMPLICATONS
About 2 cases in the above study developed complications like Epiretinal 
membrane. It was found in  patients who presented with CRVO and 
BRVO respectively with a raise in the macula thickness of more than 3 
fold.
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CME IN ASSOCIATION WITH VEIN OCCLUSION AND 
DIABETES MELLITUS
Out of 30 eyes studied, 20 eyes suffered diabetic retinopathy ofwhich 9
patients belonged to severe NPDR stage followed in order bymoderate 
NPDR(6), very severe NPDR(2 ), PDR(2), mild NPDR(1)
INTRA VITREAL INJECTIONS  AND MACULAR THICKNESS
In a country like India with high number of diabetics, visualmorbidity due 
to DME is very high. Intravitreal triamcinolone acetonideis a promising 
therapeutic method for diabetic macular edema. As ofcurrent practice, 
according to ETDRS, laser photocoagulation isadvocated for DME. 
However refractory edema can be treated withintravitreal Triamcinolone. 
Studies focused on macular edema that failedto respond to conventional 
laser photocoagulation (Martidis(25) et al.,Karacorlu(26) et al., Audren(27) et 
al., Gilles(28) et al., ophthalmology 2006)stated that IVTA is effective in 
improving vision, reducing macularthickness and inducing reabsorption 
of hard exudates in diffuse diabeticmacular edema.
In cases of macular edema due to venous occlusions, the 
recentlyconcluded SCORE(31) study clearly mentions the benefit of IVTA 
ascompared to standard therapy in CRVO. In BRVO, Triamcinolone 
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andGrid laser shows a comparable response, however triamcinolone can 
beused for macular edema not responding to laser therapy.IntravitrealAnti 
VEGF also showed a reasonably good results.
There was a significant reduction in central macular thickness in all 
patients both at 6 weeks and3 months follow up period.Maximum 
reduction in macular thickness at 6  weeks  and 3 months was observed in 
patients who had developed cystoid macular edema due to branch vein 
occlusion.
VISUAL ACUITY
All the patients treated with the intra vitreal injections showed a 
significant improvement in the visual acuity after a follow up period of 3 
months. In my study patient presenting with a vision of 5/60 improved to 
6/12 by 3 months after the treatment with IVTA. Similarly patient 
presenting with a vision of 6/36 NIG improved to vision of 6/9 after 
treatment with  intravitreal Anti VEGF. Here in my study  IVTA was 
equally effective in the treatment of CME and was found safe in patients 
with pseudophakia.
INTRAOCULAR PRESSURE
Remained  within normal limits all through the follow up periods.
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CATARACT
A recent study by Gillies(28) et al., has demonstrated that steroidrelated 
cataracts are more likely to form in patients who are steroidresponders. In 
this study , as the follow up period was only 6months,and lens changes 
were not excluded in the beginning, progression of lenschanges could not 
be assessed.
RECURRENCE OF MACULAR EDEMA
Massin(27) et al., looked at patients unresponsive to laserphotocoagulation 
and found a significant difference between CMT ofeyes injected with 
4mg IVTA and control eyes but effect was no longersignificant at 24 
weeks because of recurrence of macular edema. Thistransient reduction in 
CMT correlated also to visual acuity.
In this study, about 50% eyes needed a repeat injectionwho had a follow 
up of over 6 months due to weaning effect of the drug.
COMPLICATIONS
Refractory cases who did not show visual acuity improvementdespite 
reduction in macular thickness had complications like ERM accounting 
for 6.67%
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SUMMARY
This is a one year prospective ,non randomized clinicalTo compare the 
functional , anatomical and therapeutic  outcome of patients with cystoid 
macular oedema due to retinal vein occlusion .
The main aim was to evaluate the improvement in visual acuity 
anddecrease in macular thickness caused due to retinal  vein occlusions. 
There  was no increase in the inta ocular pressure.In this study, 30 
patients  were analysed and followed upfor a period of 6 months.
The mean age of presentation is 53.2 ± 5.6 years. The youngest patient 
was 46 years old and the oldest patient was 61 years old.
A slight male preponderance with male : female ratio of 1.9 :1
BRVO shares the highest proportion of 70% followed by CRVO (20%),  
followed by HRVO ( 6.6%) last being macular tributary vein occlusion 
(3.3.%).
Out of 30 patients  studied, 20 eyes suffered diabetic retinopathy, ofwhich 
severe NPDR outnumbered other stages.
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MACULAR THICKNESS
Based on analysis of data available, there has been a substantialreduction 
in central macular thickness after IVTA andIntravitreal anti VEGF 
administration during 6th week and 3rd  month follow up.
VISUAL ACUITY
All the patients treated with the intra vitreal injections showed a 
significant improvement in the visual acuity after a follow up period of 3 
months. In my study patient presenting with a vision of 5/60 improved to 
6/12 by 3 months after the treatment with IVTA. Similarly patient 
presenting with a vision of 6/36 NIG improved to vision of 6/9 after
treatment with  intravitreal Anti VEGF
LIMITATIONS OF STUDY
Lens changes (status) becomes a major confounding factor while 
analysing the complications of intravitreal Triamcinolone. This has not 
been addressed in the study.
While considering the weak correlation between reduction inmacular 
thickness and visual acuity improvement, the possibilityofmacular 
ischemia has to be ruled out which the study did not take intoaccount.
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Larger study group necessary to quantify the actual magnitude ofbenefit 
of this treatment modality with comparison to other therapies.Longer 
follow up is necessary to document the post injectionrecurrences and 
progression of cataract.
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CONCLUSION
Cystoid macular edema presented mostly in the 5th and 6th decadewith 
slight male preponderance.This study describes supero temporal BRVO 
as the leading etiology. 
This study describes diabetic retinopathy as associated  etiology with 
highest association with severe NPDR stage 
Among the 30 patients evaluated 26 patients accounting for about 80% 
were found to be hypertensive. This concludes that hypertension is one of 
the major risk factor in developing  retinal vein occlusion.
The fall in Mean macular thickness after IVTA ansd anti VEGF 
injections was significant in all patients  analysed.Etiologywise ,BRVO 
patients seem to be benefitted more  with greater reduction in mean 
macular thickness.Among these patients visual acuity improvement was 
on anaverage 2 Snellen line post the treatment.
Intravitreal Triamcinolone acetonide is a promising therapy inrefractory 
cystoid macular edema with established safety andeffectiveness.
Further study with a longer follow-up period and largerseries is 
warranted to assess the treatment's long term efficacy and safetyand the 
need for retreatment.
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COMPARISON BETWEEN PRE AND POST TREATMENT
MACULAR OCT
                             CASE 1
FIGURE 1: Pre injection: OCT shows cystoid spaces intraretinally with
serous macular detachment. CMT 903 μm
FIGURE 2: 3 monthsPost injection: Repeat OCT shows reduction in
cystoid spaces with macular thickness 190 μm
\
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CASE – 2
FIGURE 1: Pretreatment
FIGURE 2: Post treatment 3 months showing a reduction in CMT.
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PROFORMA:
NAME  :
AGE/SEX :
ADDRESS:
I.P NO :
CHIEF COMPLAINTS:
HISTORY OF PRESENTING ILLNESS:
H/O  defective vision / field of vision
H/O micropsia, macropsia.
             H/O diabetes, hypertension, chronic illness
PAST HOSTORY:
             H/O similar episodes in the past
             H/O diabetes ,hyperlipidemia, stroke
             H/O renal disease
H/O oral contraceptive pills.
             H/O any previous treatment , previous surgery ( cataract , ppv )
            H/O recurrent episodes of redness , watering
               H/O glaucoma
FAMILYHISTORY
             H/O  diabetes
             H/O hypertension, 
TREATMENT HISTORY
             Any medical/surgical treatment underwent earlier
GENERAL EXAMINATION
             Built
             Nourishment
             Anaemia/jaundice/cyanosis/clubbing/lymphadenopathy
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             Vitals-pulse, temperature, blood pressure, respiratory rate
OCULAR EXAMINATION
RIGHT EYE EXAMINATION LEFT EYE
Visual acuity
Eyelids
Extraocular movements
Conjunctiva
Cornea
Anterior chamber
Iris
Pupil
Lens
Fundus examination
Intraocular pressure
OTHER SYSTEMS
             CNS,CVS
OTHER CONSULTATION
             Neurology/diabetology/physician/hematology/rheumatology opinion
PROVISIONAL DIAGNOSIS
INVESTIGATIONS 
Complete hemogram with ESR ( in young patients work up for thrombophilia, auto 
antibodies, and homocystiene )
FBS, Fasting lipids
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Urine albumin and sugars
ECG , ECHO
FFA
OCT
FINAL DIAGNOSIS
TREATMENT
FOLLOWUP PERIOD
I week
III week
VI week
3 months
AS AND WHEN NEEDED
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INDEX TO MASTER CHART
SEX    -             M – Male
                          F – Female
DM -         Diabetes mellitus
                    Y – Yes
                       N – No
1– Mild NPDR
2 – Moderate NPDR
3– Severe NPDR
4– Very severe NPDR
5 – PDR
HT -  Hypertension
Y – Yes
N – No
EYE AFFECTED - RE – Right eye
LE – Left eye
DIAGNOSIS –
1 –Central retinal vein occlusion with cystoid macular edema
2 –  Branch Retinal vein occlusion with CME
3 – Hemi Retinal vein occlusion with CME
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4 – Macular Tributary vein occlusion
VA – Visual acuity
PH – Pin hole
NIP – Not improving with pinhole
IOP – Intraocular pressure (in mmHg)
OCT – Optical coherence tomography
CMT – Central macular thickness (in μm)
CPL – complications 
ERM – Epi retinal membrane
TREATMENT
V – intravitreal anti VEGF injections (ranibizumab )
T – intravitreal triamcinolone injection 
NAME AGE SEX COMPLAINTS DM HTN EYE AFFECTED DIAGNOSIS VN ON PRESENTAION CMT IOP( mmhg ) Treatment VN 3WEEK VN 6 WEEK VN 3 MONTH CMT 6 WK CMT 3MT CMPL
SHANKAR 48 M DV, F,  y3 Y RE 2 2/60 NIG NIP 664 16 V 2/60 NIG NIP 2/60 NIG NIP 3/60NIG NIP 540 480 -
KARUPAYI 54 F DV, F, M Y4 Y RE 2 6/36 NIG NIP 345 14 T 6/36 NIG NIP 6/36 NIG NIP 6/36 NIP 280 280 -
FATIMA 55 F DV,FL, Y3 Y RE 2 6/36 NIG NIP 380 16 V 6/36 NIG NIP 6/18 NIG NIP 6/9 NIP 234 210 -
VIJAYA 53 F DV, F, y1 Y RE 2 3/6 0NIG NIP 550 14 V 3/60 NIG NIP 4/60 NIG NIP 4/60 NIP NIG 446 390 -
RANGANTHAN 47 M DV, M,F Y5 Y RE 1 1/60 NIG NIP 903 14 V 1/60 NIG NIP 1/60 NIG NIP 2/60 NIG NIP 780 540 ERM
ARUMUGAM 45 M DV, F Y5 N RE 2 5/60 NIG NIP 448 16 T 5/60 NIG 6/60 NIG 6/60 NIP 347 304  -
VIJAY KUMAR 54 M DV, F Y4 Y RE 2 6/24 NIG NIP 307 18 V 6/24 NIG NIP 6/18 NIG NIP 6/12 NIP 230 190  -
ELLAPPA 58 M DV, F Y3 N LE 2 5/60 NIG NIP 448 14 V 5/60 NIG 5/60 NiG 6/60 NIP 380 310  -
MALLA REDDY 59 M DV, M N N RE 1 1/60 NIG NIP 846 16 V 3/60 NIG NIP 3/60 NIG NIP 4/60 NIP NIG 640 420  -
POONGODAI 51 F DV, M y2 Y RE 2 5/60 NIG NIP 448 18 V 6/36NIG NIP 6/18 NIG NIP 6/12 NIP 238 238  -
MARY 49 F DV, FL Y2 Y RE 1 2/60 NIG NIP 776 14 V 3/60 NIG NIP 3/60 NIG NIP 4/60 NIP NIG 550 420  -
RAJESH 48 M DV, FL Y3 Y LE 2 3/60 NIG NIP 689 16 V 3/60 NIG NIP 3/60 NIG NIP 4/60 NIP NIG 546 434  -
KAVIN RAJ 55 M DV, FL N Y LE 2 3/60 NIG NIP 654 18 V 4/60 NIG NIP 5/60 ph 6/60 6/36NIP 442 310  -
MAGESAN 52 M DV, M,F Y2 Y LE 2 4/60 NIG NIP 567 12 T 5/60 NIG 5/60 NiG 6/60 NIG NIP 452 380  -
SEKAR 58 M DV, M Y2 Y RE 2 5/60 PH 6/60 456 18 V 6/24 NIG NIP 6/18 NIG NIP 6/18 ph 6/9 231 190  -
RAJA 54 M DV, F N Y RE 2 6/60 NIG NIP 434 16 T 6/36 NIG NIP 6/36 NIG NIP 6/36 NIG NIP 338 304  -
MUNNIYAMMAL 61 F DV, FL , M Y3 Y LE 3 4/60 NIG NIP 565 14 V 5/60 ph 6/60 6/60 NIG 6/36NIP 436 330  -
SELVI 48 F DV , F, N Y LE 2 5/60 NIG NIP 578 16 V 5/60 NIG 6/60 NIG 6/36 NIG NIP 446 390  -
KASTURI 49 F DV, F Y3 N LE 4 6/36 NIG NIP 345 16 T 6/24 NIG NIP 6/24 ph 6/12 6/12 NIP 290 234  -
REVATHI 57 F DV, F , M N N RE 2 6/60 NIG NIP 567 18 V 6/36 NIG NIP 6/36 NIG NIP 6/24NIG NIP 430 330  -
RAVIKUMARAN 54 M DV, F Y2 Y RE 1 5/60 PH 6/60 445 14 T 6/36 NIG NIP 6/36 NIG NIP 6/24 NIG NIP 326 304  -
MAHALAKSHMI 46 F DV, F Y3 Y RE 2 2/60 NIG NIP 887 12 V 2/60 NIG NIP 2/60 NIG NIP 4/60 NIP NIG 645 430 ERM
SELVARAJ 55 M DV, M N Y LE 2 5/60 PH 6/60 567 14 V 6/60 NIG NIP 6/60 NIG 6/36NI P 454 348  -
MOHAN KUMAR 56 M DV, M y3 Y LE 1 5/60 NIG NIP 590 16 V 6/36 NIG NIP 6/36 NIG NIP 6/24 NIG NIP 490 330  -
DELLI BABU 52 M DV, FL, M N Y LE 2 6/60 NIG NIP 446 18 T 6/60 NIG NIP 6/60 NIG 6/36 NIG NIP 345 310  -
POONGAVANAM 58 F DV, FL N Y RE 2 4/60 NIG NIP 678 16 V 6/60 NIG NIP 6/60 NIG 6/36 NIG NIP 565 310  -
RAJALAKSHMI 47 F DV, M y 3 Y LE 1 5/60NIG NIP 604 18 V 5/60 NIG 5/60 NiG 6/60 NIG NIP 540 420  -
NAGAMMAL 58 F DV, FL. M N Y RE 3 6/ 60 NIG NIP 578 16 V 6/60 NIG NIP 6/60 NIG 6/36 NIP 468 310  -
DURAI PANDI 59 M DV, F Y3 Y RE 2 6/60 ph 6/36 567 18 V 6/60 NIG NIP 6/60 NIG 6/36 NIG NIP 446 360  -
CHINNA THAMBI 56 M DV, F, L N Y RE 2 6/60 NIG NIP 456 14 V 6/36 ph 6/18 6/18 NIG NIP 6/12NIG NIP 330 210  -
